Egetis Therapeutics AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	62.4	46.1	57.6	22.6	38.2
Revenue	62.4	46.1	57.6	22.6	38.2
Revenue Growth (YoY)	35.36%	-19.96%	154.87%	-40.84%	-6.05%
Cost of Revenue	50	11.6	11	142.6	96.6
Gross Profit	12.4	34.5	46.6	-120	-58.4
Selling, General & Admin	201	215.3	172.8	74.3	44.6
Research & Development	158.3	146.2	194	-	-
Other Operating Expenses	-6.9	-5.2	-8.9	-	-0.3
Operating Expenses	352.4	356.3	357.9	77	46.8
Operating Income	-340	-321.8	-311.3	-197	-105.2
Interest Expense	-22.7	-17.6	-4.2	-0.1	-0.2
Interest & Investment Income	13.3	6.9	4.9	0.9	0.1
Currency Exchange Gain (Loss)	-	-6.3	-13.4	2.4	0.6
Other Non Operating Income (Expenses)	7.3	-4.5	-2.8	-	0.2
Pretax Income	-342.1	-343.3	-326.8	-193.8	-104.5
Income Tax Expense	0.4	0.3	0.1	-	-
Net Income	-342.5	-343.6	-326.9	-193.8	-104.5
Net Income to Common	-342.5	-343.6	-326.9	-193.8	-104.5
Shares Outstanding (Basic)	368	307	257	194	180
Shares Outstanding (Diluted)	368	311	260	194	180
Shares Change (YoY)	18.43%	19.57%	33.86%	7.97%	166.96%
EPS (Basic)	-0.93	-1.12	-1.27	-1.00	-0.58
EPS (Diluted)	-0.93	-1.12	-1.30	-1.00	-0.60
Free Cash Flow	-268.5	-227.9	-278.4	-173.5	-130.3
Free Cash Flow Per Share	-0.73	-0.73	-1.07	-0.89	-0.72
Gross Margin	19.87%	74.84%	80.90%	-	-152.88%
Operating Margin	-544.87%	-698.05%	-540.45%	-871.68%	-275.39%
Profit Margin	-548.88%	-745.34%	-567.53%	-857.52%	-273.56%
Free Cash Flow Margin	-430.29%	-494.36%	-483.33%	-767.70%	-341.10%
EBITDA	-308.53	-319.1	-310.2	-195.8	-104
EBITDA Margin	-	-	-	-	-272.25%
D&A For EBITDA	31.47	2.7	1.1	1.2	1.2
EBIT	-340	-321.8	-311.3	-197	-105.2
EBIT Margin	-	-	-	-	-275.39%
Revenue as Reported	-	-	-	22.6	38.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.